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Background: COVID-19 has already claimed a considerable number of lives worldwide. However, 
there are concerns with treatment recommendations given the extent of conflicting results with 
suggested treatments and misinformation, some of which has resulted in increased prices and 
shortages alongside increasing use and prices of personal protective equipment (PPE). This is a 
concern in countries such as India where there have been high patient co-payments and an 
appreciable number of families going into poverty when members become ill. However, balanced 
against pricing controls. Community pharmacists play a significant role in disease management in 
India, and this will remain. Consequently, there is a need to review prices and availability of pertinent 
medicines during the early stages of the COVID-19 pandemic in India to provide future direction. 
Objective: Assess current utilisation and price changes as well as shortages of pertinent medicines 
and equipment during the early stages of the pandemic. Our Approach: Multiple approach involving 
a review of treatments and ongoing activities in India to reduce the spread of the virus alongside 
questioning  pharmacies in selected cities from early March to end May 2020. Our activities: 111 
pharmacies took part, giving a response rate of 80%. Encouragingly, no change in utilisation of 
antimalarial medicines in 45% of pharmacies despite endorsements and for antibiotics in 57.7% of 
pharmacies, helped by increasing need for a prescription. In addition, increased purchasing of PPE 
(over 98%). No price increases were seen for antimalarials and antibiotics in 83.8% and 91.9% of 
pharmacies respectively although shortages were seen for antimalarials in 70.3% of pharmacies, 
lower for antibiotics (9.9% of pharmacies). However, price increases were typically seen for PPE (over 
90% of stores) as well as for analgesics (over 50% of pharmacies). Shortages were also seen for 
PPE (88.3%). Conclusion: The pandemic has impacted on utilisation and prices of pertinent 
medicines and PPE in India but moderated by increased scrutiny. Key stakeholder groups can play a 
role with enhancing evidenced-based approaches and reducing inappropriate purchasing in the 
future. 
 
1. INTRODUCTION/ BACKGROUND 
 
1.1 Healthcare system in India and role of community pharmacists 
Until recently, healthcare in India has largely been funded through out-of-pocket payments, with 
payments relatively stagnant at between 69% to over 75% of total healthcare expenditure (1-3). The 
cost of medicines accounted for an appreciable proportion of this at over 60% of total expenditure and 
over 70% of out-of-pocket expenditures (2, 4), which is similar to other lower- and middle-income 
countries (LMICs) (5). These out-of-pocket expenses have potentially catastrophic consequences if 
family members become ill, exacerbated by an increase in non-communicable diseases (NCDs) in 
India in recent years. As a result, up to 39 million people are pushed into poverty each year in India 
due to healthcare payments (1, 2, 6, 7). This is beginning to change with ongoing reforms to provide 
health insurance coverage for up to 100 million families in poverty (3, 7); however, this will take time 
in view of a number of challenges including patient enrolment, agreeing the future role of physicians, 
necessary strengthening of regulatory systems and increasing the percentage of gross domestic 
product (GDP) spent on health (3, 7, 8). These reforms will also involve improving healthcare delivery 
in rural areas to address current inadequacies, for instance through the instigation of 150,000 health 
and wellness centres as healthcare facilities (3, 9).  
 
In view of the contribution of the costs of medicines to total healthcare costs in India, coupled with 
existing high co-payments for visiting physicians and funding medicines, community pharmacies have 
and will continue to play an appreciable role in managing patients in India (10-14).  Key reasons 
include avoiding paying physician fees, especially for milder symptoms, accessibility with long 
opening hours, and a lack of queues compared with ambulatory care clinics (10, 15, 16). As a result, 
community pharmacists in India are the first point of healthcare professional contact for up to 40% of 
patients with tuberculosis (TB) symptoms and an appreciable number of patients continue to seek 
their advice after diagnosis (10).  
 
Overall, community pharmacists in India play a crucial role in optimizing the use of medicines and 
improving patient outcomes whilst seeking to prevent the misuse of medicines (13, 15). This is similar 
to their roles in other countries where they are often the first healthcare professional patients consult 
regarding their illness, and they are increasingly involved in the management of chronic and other 
diseases (12, 17-19). The cost of medicines to patients have been helped in recent years by ongoing 
reforms since 2013 to fix prices for essential medicines as well as encourage the prescribing of 
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generic medicines where possible (20-22). However, concerns have been raised about the knowledge 
of pharmacists regarding pharmaceutical care, the actual extent of pharmaceutical care activities 
undertaken in practice, and the continued self-purchasing of antibiotics that exists despite legislation, 
which along with increased utilisation rates of antibiotics in recent years has led to increased 
antimicrobial resistance (AMR) (4, 11, 23, 24).  
 
Reforms are also needed in India regarding the management of NCDs, with NCDs now the leading 
cause of death in India. NCDs accounted for 60% of all deaths in India in 2014 alongside continued 
high rates of infectious diseases including TB and growing AMR rates (1, 10, 23). The growing burden 
of NCDs including cardiovascular disease (CVD), hypertension, and diabetes, coupled with the 
associated need for medicines, will appreciably increase healthcare costs unless addressed, 
alongside increasing expenditure on antimicrobials with increasing utilisation (23, 25-28).  
 
It is likely therefore that any Government activities to transfer funds and personnel to tackle COVID-19 
will impact on planned activities to reduce the growing burden of NCDs in India as well as any 
planned activities surrounding other infectious diseases including reducing AMR rates. Consequently, 
existing healthcare needs and activities need careful monitoring to reduce the extent any unintended 
consequences arising from the pandemic. 
 
1.2 COVID-19 and risk factors 
The COVID-19 pandemic was first identified Wuhan in China in December 2019, quickly spreading to 
all continents (29-31). By 27 September 2020 there were 32.73 million cases with over 990,000 
deaths worldwide, giving a case fatality ratio (CFR) among confirmed cases of 3.03% (32). This 
included over 6.72 million confirmed cases in the WHO South East Asian Region including India, with 
over 110,000 deaths, giving a CFR of 1.65% (32). It is recognised that there has been appreciable 
under-reporting of prevalence rates and deaths in a number of South East Asian countries with a lack 
of testing capabilities, particularly at the beginning (33-35).  
 
COVID-19 is transmitted from person to person principally through respiratory droplets and aerosol 
transmission, alongside direct contact with contaminated surfaces, forming the basis of preventative 
measures (36-42). Increased morbidity and mortality from COVID-19 appears to be associated with a 
number of underlying health conditions including CVD, hypertension, diabetes, chronic obstructive 
pulmonary disease (COPD), shortness of breath, smoking and blood types (43-50). Ethnicity may also 
be important with patients in the United Kingdom of Indian origin at appreciably increased risk of dying 
from COVID-19 versus those of white ethnicity (51-54). Smoking is also an issue in India with high 
rates particularly among men (55-57); however, rates appear to be decreasing following the 




1.3 Response to COVID-19 and concerns in India 
The first reported cases in India for COVID-19 were in Kerala, on 30 January 2020 (31, 59, 60).  As of 
27 September 2020, 5.992 million confirmed cases and over 94,000 deaths have been reported in 
India due to COVID-19, the highest rates in the WHO South East Asia region and giving a CFR of 
1.58%. This is likely to be an underestimate though with lack of testing and capacity issues certainly 
during the early stages of the pandemic until the number of testing facilities appreciably increased 
with the help of the private sector (Box 1), exacerbated in some cases by patients having to cover the 
high costs of tests although this is now changing (33, 61). By late March, there were only 18 tests 
being undertaken per million population in India versus 6931 per million in South Korea (60). By 25 
April, over 5.79 million tests had been undertaken, from data supplied by the Indian Council of 
Medical Research (ICMR) (62). Other reports suggest a cumulative total of 3.8 million tests by 1 June 
2020 also citing ICMR. The testing rates at the end of May/ beginning of June were still only 0.08 per 
1,000 people in India versus 1.02 in Italy and 1.16 in the USA (63). Since then, with the help of  an 
appreciable increase in the number of testing facilities and increased production of testing equipment 
(63, 64), the cumulative number of tests as of 8 July 2020 was over 110 million with 1132 laboratories 
now involved with testing throughout India (Box 1) (65, 66). ICMR has also recently approved the use 
of a point-of-care rapid antigen test to aid early detection of COVID-19 to further enhance the 
numbers tested to aid the ‘test-track-treat’ strategy (67, 68).  
 




• Different methods are used to test for COVID-19. These include: 
o ICMR-validated PT-PCR (reverse transcription polymerase chain reaction test)  
o MolBio Diagnostics’ Truenat (completely indigenous diagnostic platform - (69)) 
o Cepheid’s cartridge-based GeneXpert (cartridge-based nucleic acid 
amplification test) 
• Facilities for the various testing approaches as of 31 May 2020: 
o Real-time RT-PCR: 481 facilities - government: 313 and private: 168 
o Truenat test for COVID-19: 140 facilities - government: 131 and private: 9 
o CBNAAT for COVID-19: 55 facilities - government: 28 and private: 27 
• Facilities for the various testing approaches as of 8 July 2020: 
o Real-time RT-PCR: 603 facilities - government: 373 and private: 230 
o Truenat test for COVID-19: 435 facilities - government: 400 and private: 35 
o CBNAAT for COVID-19: 94 facilities - government: 33 and private: 61 
 
India faces ongoing challenges with preventing the spread of COVID-19, including issues with social 
distancing in big cities with crowded streets, lack of access to clean water, lack of regular hand 
washing facilities in an appreciable number of households, lack of physicians, lack of hospital beds (at 
0.5 to 0.7 beds per 1,000 compared with 4.3 per 1000 in China) and ICUs versus higher income 
countries, just 20,000 ventilators in the country, and a lack of personal protective equipment (PPE) 
among healthcare professionals (60, 70-76). 
 
There are also challenges with high co-payments for treating existing infectious and non-infectious 
diseases, which will be exacerbated by diverting expenditures towards prevention and management 
of COVID-19, as well as purchasing basic necessities if incomes are reduced as a result of the 
pandemic (60, 71). This is in addition to concerns about the routine availability of medicines to treat 
priority diseases in India. Medicine prices are typically lower in India compared with a number of other 
low and middle-income countries (LMICs) although appreciable variation in prices has been seen 
among pharmacies (77-79).  Having said this, as mentioned, there are ongoing activities by the Indian 
Government to regulate the prices of medicines in India to help with co-payments for essential 
medicines (20, 21). Purchasing personal protective equipment (PPE) remains an issue with the costs 
of the materials to make PPE appreciably increasing following the pandemic (80); however, prices 
and shortages may be alleviated by increased local production along with pricing and manufacturing 
regulations (74, 81, 82).   
 
Ongoing national and regional activities during the early stages of the pandemic to help reduce the 
spread of COVID-19, as well as the financial consequences, are contained in Table 1. It was 
perceived that timely decisions to introduce lockdowns helped with controlling infection rates initially 
although at a negative socioeconomic cost (62). However, we are now seeing a spike in infection 
rates  as lockdown measures are relaxed despite warnings to maintain social distancing and as a 
consequence of the recent monsoons (33, 83). Consequently, there has been a re-instigation of such 






Table 1 – Range of national and regional activities in India in 2020 from January 2020 up to June 
2020 to help reduce the spread of COVID 19 and its impact 
 
Activities Details of activities including timelines during 2020 where 
documented 
Healthcare Activities • 30 January 2020 – Surveillance is being strengthened at points of 
entry into the country and in the community and the WHO issued 
advice to patients on hand sanitisation and other measures (59) 
• 6 February 2020 – The Government issued travel restrictions to 
China and anyone with a travel history from China from 15th 
January 2020 will be quarantined (86). The WHO is also working 
with key Government and other groups to offer support and help 
(86). During this period, the Ministry of Health instigated a 24 h/7 
days-a-week disease alert helpline to provide information including 
clinical guidance (31, 87), with the alcohol industry engaged in 
developing hand sanitisers and the textile industry producing PPE 
to address shortages (74) 
• 8 March 2020 – 52 laboratories were identified by ICMR for 
undertaking testing for COVID-19 (88) (now expanded – Box 1). In 
addition, all international passengers irrespective of nationality are 
now mandated to undergo universal medical screening at airports 
with screening facilities in place at 30 airports and WHO India is 
supporting capacity building and training across India (88). Those 
arriving from China, France, Germany, Italy, Iran, Republic of 
Korea, Spain and Germany after 15 February 2020 to be 
quarantined for a minimum of 14 days starting 13 March 2020 (89) 
• 15 March 2020 - all movement suspended for foreigners through 
all Immigration Land Check Posts at Bangladesh, Nepal, Bhutan 
and Myanmar border will be suspended with only a few exceptions 
(Nepalese and Bhutanese nationals) 
• 22 March 2020:  
o ‘Janata Curfew’ introduced with 14 hour lockdown (31). In 
addition, all train services suspended until 31 March, 
although Goods Trains may continue for essential 
commodities, and all children under 10 and all elderly over 
65 to remain at home at avoid mass gatherings unless a 
medical reason or for essential services (90) 
o Ministry of Pharma and Consumer Affairs instructed to 
take necessary action to regulate the price for PPE and 
other health related materials and to facilitate their 
availability in hospitals and to the population at large (90) 
o WHO working with ICMR to enhance the testing strategy 
(90) (now appreciably expanded – Box 1), with ICMR 
issuing guidelines for the clinical management of patients 
with COVID-19 
• 25 March 2020: 
o Further lockdown measures initiated for 21 days starting 
on 25 March  (31, 60, 91), and extended to 3 May (31) 
o India introduced an export ban on hydroxychloroquine but 
later rescinded as seen in for instance Malaysia (92, 93) 
• April 2020 – ICMR issued national guidelines for Ethics 
committees reviewing Biomedical and health research during the 
COVID-19 Pandemic (94) 
• 14 April 2020 – Lockdown extended until 3 May 2020 (95) 
• 1 May 2020 – Further lockdown extended for 2 weeks from 4 May 
2020; however, variable activities across districts depending on 
current infection rates (96) 
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• 1 June 2020 – Still strict enforcement of lockdown in containment 
zones with re-opening of activities outside of containment zones 
(97) 
• 26 June – Indian railways will not resume a regular service until at 
least 12 August due to a spike in cases (33) 
Financial and 
socioeconomic activities 
• The Government in India announced US $2.1 billion aid to help 
the health sector fight the pandemic (62) 
• 27 March 2020 – Government announces a $22.6 billion stimulus 
package to aid poorer communities affected by lockdown 
measures (98) 
• End March 2020 – Interest rates reduced, Tata Group has 
donated approximately $200 million and Aditya Birla Group 
approximately $70 million to fight the spread of the pandemic and 
provide medical supplies (99)  
• 13 May 2020 – Prime Minister promises a $266 billion package to 
protect economy from Covid-19 (100) 
 
Currently, there is not a cure for COVID-19; however, a number of medicines have been proposed 
and are undergoing trials (101, 102). Recently, dexamethasone has been shown in the UK Recovery 
Trials to reduce deaths in ventilated patients and in those receiving oxygen only (103, 104). 
Remdesivir has shown encouraging results in a recent study after earlier concerns over an 
underpowered study (105-107). However a recent study among moderate patients failed to show 
similar benefit with remdesivir still being considered as experimental (108, 109),  . Triple antiviral 
therapy is also showing promise in the management of COVID-19 patients although numbers are 
small (110); however, more studies are needed before any recommendations can be made. In 
addition, an appreciable number of vaccines are now in development (111, 112).  
 
However, there is still considerable controversy surrounding the use of chloroquine and 
hydroxychloroquine with or without azithromycin for both prevention and treatment of COVID-19, 
following initial studies in China (113-116). Internationally, concerns were raised about the lack of 
comparisons in the initial studies as well as potential harms including cardiac side-effects (115, 117-
122). Subsequent studies, including registry studies, have enhanced these concerns for 
hydroxychloroquine for both the prevention and treatment of COVID-19 (116, 121, 123-126). 
Consequently, the European Medicines Agency has advised against its prescribing outside of clinical 
trials (127) and Das et al. (2020) in India also advised caution (126). The study by Mehra et al. (2020) 
also showed increased mortality with chloroquine or hydroxychloroquine; however, this paper has 
now been retracted and is currently subject to external auditing (128, 129). In view of recent studies 
including the UK Recovery trial, the WHO has now halted the hydroxychloroquine arm in the ongoing 
Solidarity Trial and the National Institute of Health in the US has also halted the use of 
hydroxychloroquine in its studies (107, 124, 130-132).  
 
Having said this, the ICMR under the Ministry of Health and Family Welfare in India continues to 
recommend hydroxychloroquine for prophylaxis despite potential concerns (31, 133-136). In a 
recently published case controlled study, Chatterjee et al. (2020) demonstrated that the prescribing of 
four or more maintenance doses of hydroxychloroquine was associated with a significant reduction in 
the odds of healthcare workers getting COVID-19 (137). Other treatments initially recommended by 
ICMR and others include lopinavir- ritonavir, although there is contrasting data regarding its 
effectiveness in COVID-19 patients (31, 138, 139). More recently, the WHO has discontinued the 
lopinavir- ritonavir arm of the Solidarity trial with the interim results showing this combination 
demonstrated little or no reduction in the mortality of hospitalized COVID-19 patients when compared 
to standard of care (132). Overall, further studies are needed before specific treatments can be 
robustly recommended given the continuing concerns with a number of treatments, the redaction of 
recent studies and issues with study design and setting (117, 128, 140-142). 
 
We are aware the endorsement of hydroxychloroquine has resulted in appreciably increased use in a 
number countries and localities along with increased prices, although there have been 
hospitalisations and deaths from poisoning (122, 143-149). Increased prices can be a concern in India 
with potentially detrimental consequences for families if limited available funds for priority disease 
areas including NCDs are being diverted towards purchasing treatments where there are ongoing 




1.4 Study aims and objectives 
In view of the current situation in India, we believed there was an urgent need to assess the impact of 
COVID-19 on the availability and prices of medicines and other technologies to prevent and treat 
COVID-19 in community pharmacies. The key considerations are the high rates of both infectious and 
non-infectious diseases in India, issues with sanitation and crowded streets, the catastrophic 
consequences for families when members become ill, and fears regarding the availability of regular 
medicines during the pandemic (1, 2, 150). Community pharmacists are a particular target since they 
currently play a key role in the management of diseases in India, with ongoing issues with access to 
physicians and high co-payments especially in rural areas (10, 11, 13). They are also in a good 
position to suggest to patients with more severe symptoms that they seek additional help (151). This 
is important since it is known it can be difficult to differentiate respiratory tract infections from COVID-
19 in patients presenting with coughs and fever (152). 
 
We have seen prices rise for essential medicines in LMICs over time and for treatments for COVID-
19, as well as appreciable price increases for the materials to make PPE in India following the start of 
the pandemic. It is important to evaluate the current situation in India regarding pertinent medicines 
and PPE to provide future guidance at this critical time  (80, 143, 153). Consequently, we sought to 
address this through direct contact with community pharmacists across India. However, we are aware 
of government regulations regarding the pricing of essential medicines in India (20, 21). As a result, in 
this initial study we sought to assess the utilisation, availability and price changes of medicines and 
PPE for COVID-19 among a number of cities across India to provide future direction to key 
stakeholder groups in India. Senior level co-authors would also be targeted to provide guidance 
based on their experiences across LMICs. 
 
We have not assessed the influence of the various Government initiatives (Table 1) on the prevalence 
and mortality of COVID-19 in India. We are aware of the concerns about the testing rates for COVID-
19 certainly initially as well as evolving strategies to address ongoing spikes in infection rates as 
lockdown measures are eased and with the advent of the monsoons (33, 83). We will though be 
monitoring morbidity and mortality rates alongside the unintended consequences of lockdown and 
other measures given rising prevalence rates of COVID-19 in India and existing high prevalence rates 
for both infectious and non-infectious diseases, and will be reporting on this in future studies. 
Unintended consequences include issues of increased gender violence as well as mental health 
issues associated with any stigma associated with COVID-19 as well as lockdown measures (154-
156). In addition, rising rates of NCDs especially if patients cannot attend clinics or receive their 
medicines due to lockdown measures as well as have affordability issues with medicines through lack 




We initially undertook a narrative review of the current situation regarding COVID-19 in India and on 
suggested treatments. We subsequently undertook quantitative research in the form of a survey. The 
narrative review included a review of current and proposed treatment approaches including vaccines 
and recommendations for preventing and managing COVID-19, including the role of community 
pharmacists as well as issues of misinformation. We did not systematically review the papers or other 
information sources for their quality using well-known scales such as the Newcastle-Ottawa scale as 
some of the papers quoted are in pre-publication format and we have used a considerable number of 
internet sources (159). However, the publications and internet sources were filtered by the co-authors 
to add robustness to the paper and its suggestions. 
 
The information sourced from the pragmatic review of the literature was combined with a 
questionnaire survey among community pharmacies (Appendix 1) to assess the situation regarding 
prices, availability and usage patterns of carefully selected medicines that could potentially be used in 
the management of COVID-19, as well as PPE, soon after the start of the pandemic.  
 
For this rapid analysis, we selected via purposive sampling representation of pharmacies from all 
parts India. This included Jodhpur and Ahmedabad as part of Western India, Chaibasa and Kolkata 
as part of Eastern India, Delhi in northern India and Pune in Southern India. Convenience sampling in 
these cities was used to select pharmacists through emails, telephone contact, personal contacts and 
other mechanisms. There was no sample size calculation as there was no previous data in India to 
8 
 
base calculations upon. However, the intention was to undertake the research among an appreciable 
number of community pharmacies across India to gain good insights and provide a basis for future 
studies if needed. 
 
Key questions were to assess patterns of demand, availability, and price changes of selected 
medicines and equipment, as well as the potential future role of pharmacists to reduce 
misinformation. These are contained in Box 2 (building on Appendix 1). Those conducting the 
research were provided with an Excel spreadsheet of the questions to complete. The questions were 
open ended as we were aware that in a number of situations we would be unable to obtain exact 
details of changes in utilisation patterns and prices; however, we wanted to capture data including 
more general information for this initial study. The answers were collated where possible into logical 
bands for comparisons with other countries such as Bangladesh (147). These bands were not pre-
defined as this was an exploratory rapid pilot study, with changes in prices based on local prices. In 
addition, general information would be sufficient if the pharmacists were unable to be specific given 
the exploratory nature of this study. 
 
Box 2 – Open ended questions to community pharmacists in India regarding pertinent medicines and 
equipment to prevent and treat COVID-19 
 
• Geographic location (Region) 
• What changes in medicine purchasing patterns have you noticed in your pharmacy from the 
beginning of March until the end of May for antimalarials (hydroxychloroquine), antibiotics (e.g. 
azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics based on 
invoices where possible or other information sources; alternatively, impressions. Similarly for 
any shortages of these medicines during the same period 
• What changes in medicine prices have you noticed for targeted medicines from the beginning 
of March until end May for antimalarials, antibiotics, multivitamins and analgesics (based on 
invoices or other information sources where possible) 
• Similarly, for PPE (utilisation, prices and shortages) - beginning of March until the end May - 
based on invoices or other information sources/ impressions 
• Any suggestions for addressing inappropriate self-medication for the future including 
addressing misinformation and its potential catastrophic consequences for patients? 
 
The pharmacists were briefed on the objectives of the study with the option to participate or not, with 
confidentiality maintained throughout. Our hypothesis, based on findings in other countries, was that 
there would be shortages of some of the medicines, although countered in India as a chief producer 
of medicines with export bans in place certainly initially (92)Price rises especially for medicines 
potentially tempered though by the Ministry of Pharma and Consumer Affairs being instructed to take 
necessary action to regulate these for PPE and other health related materials alongside existing 
regulations for (Table 1) (90). The findings were compiled into a tabular format. No formal statistical 
analysis was performed as the level of detail varied considerably across the pharmacies.   
 
We subsequently combined the data collected using the experience of the co-authors regarding key 
issues including pharmaceutical care, health policy and self-purchasing in LMICs to provide future 
direction, building on comments from the interviewed pharmacists. We have previously successfully 
used this approach to provide future direction in LMICs (160-165).  
 
Ethical approval for this study was not required according to national legislation and institutional 
guidelines. However, all pharmacists freely provided the requested information having been given the 
opportunity to refuse to participate if wished. This is in line with previous studies undertaken by the 
co-authors in related areas including analysis of policies to enhance the rationale use of medicines 
and biosimilars, pricing policies and issues surrounding generics, which involved direct contact with 




Overall, 135 pharmacies were visited to give a response rate of 82% (Table 2). 
 




 How many pharmacies 
approached 
(in Number)  
How many accepted 
to take part (in 
Number) 
How many refused (in 
Number) 
Group 1 69 56 13 
Group 2 66 55 11 
Total (Total and 
%) 
135 111 (82%) 24 (18%) 
NB – Groups 1 and 2 refer to the consolidation co-ordination of the findings by the principal co-author involved 
 
The pharmacies were located throughout India (Figure 1, Table 3). 
 
Figure 1 – Location of participating pharmacies in India 
 
 
Table 3 – Community Pharmacy location in India  
 
Location – City and State Number of pharmacies where data was 
collected 
JODHPUR, Rajasthan 44 
CHAIBASA, Jharkhand  12 
Delhi, Union Territory 15 
Ahmedabad, Gujarat. 15 
Kolkata, West Bengal  15 
10 
 
Pune, Maharashtra 10 
Total  111 
 
We first report on changes in utilisation patterns before reporting on any price changes seen with the 
various medicines and equipment (Box 2) as well as any shortages. The reported figures are absolute 
figures based on interviewee feedback. 
 
3.1 Utilisation 
Table 4 depicts changes in utilisation patterns for the various medicines, vitamins and PPE equipment 
and hand sanitisers from the beginning of March until the end of May 2020. Encouragingly, no change 
or decreased utilisation of antimalarials was seen in 45% of pharmacies taking part, with similarly 
limited increases in the utilisation of antibiotics (42.3% of pharmacies taking part). An appreciable 
increase in antibiotic utilisation was seen though in a small number of pharmacies.  
 
Encouragingly, there was an increase in the purchasing of PPE and vitamins to boost the immune 
system in over 90% of pharmacies taking part, nearing 100% for PPE. It is likely that we will continue 
to see such increases in the purchasing of both of these if COVID-19 infection rates continuing to 
increase following any easing of lockdown measures.   
 
Table 4 – Utilisation changes for medicines and PPE between beginning March 2020 and end May 
2020 among 111 pharmacies in India 
 
 
NB: No change also includes situations where not dispensed without a prescription (antimalarials and antibiotics) 
 
3.2 Price changes 
Table 5 depicts price changes for pertinent medicines and PPE. Encouragingly, there were limited 
price changes for antimalarials (only 16.2% of the pharmacies) and antibiotics (8.1% of the 
pharmacies). Contrasting with this, price increases were seen for PPE among over 90% of the 
pharmacies taking part in the study. This was only a slight increase, or an increase in only one of the 





boosters Face masks/ PPE
Decrease (including due to 
prescription required and no 
prescription) 25 23 21 1
No change 25 41 15 10 2
Slight increase 10 5 1 2
Increase (not specified) 49 30 62 79 54
1.5 to 2 fold increase 1 3 2
2 to 3 fold increae 2 3 9 3
4 to 5 fold increase 1 1 6 3
Over 5 fold increase 6 3 8 49
Total 111 111 111 111 111
No change/ decrease 50 64 36 11 2
% of total 45.0 57.7 32.4 9.9 1.8
Increase % 55.0 42.3 67.6 90.1 98.2
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Table 5 – Price changes for medicines and PPE between beginning March 2020 and end May 2020 




3.3 Medicine and prevention shortages 
Perhaps not surprisingly, shortages of some medicines and PPE were seen among the pharmacies in 
India (Table 6). These were principally confined to antimalarial medicines (70.3%) and PPE (88.3%).  
 
Table 6 – Shortages for medicines and PPE between beginning March 2020 and end May 2020 




3.4 Potential ways forward to address misinformation and enhance appropriate use of 
medicines and equipment across sectors 
 
Possible strategies based on interviewee and co-author feedback to address misinformation and 
other concerns regarding the management of COVID-19 and any unintended consequences are 
included in Table 7. We believe this is especially important for patients with NCDs given rising rates in 
India, and we will be researching this further. 
 
Table 7 – Key activities among stakeholder groups to improve prevention and management of 
patients with COVID-19  
 
Stakeholder Group Suggested Activities 
Government • Encourage an evidence-based environment for key 
recommendations and pronouncements especially when 
proposing activities to prevent and treat COVID-19. This is 
particularly important given the controversies that continue to 
surround hydroxychloroquine and family resources spent on 
recommended treatments for the management of COVID-19 will 
mean less monies for other medicines and food especially 
among patients with existing diseases including chronic NCDs 
Antimalarials Antibiotics Analgesics
Vitamins/ immune 
boosters Face masks/ PPE
Decrease 1
No change 93 102 84 51 10
Slight increase (including only 
one month out of the 3) 10 2 2 2 44
Increase (not specified) 2 3 19 49 52
Up to 2 fold
2 to 3 fold increase 1 4 4 4 1
3 to 4 fold increase 1 2 1
4 to 5 fold increase 2 3 2
Over 5 fold increase 3 1
Total 111 111 111 111 111
No change/ decrease 93 102 85 51 10
% of total 83.8 91.9 76.6 45.9 9.0
Increase % 16.2 8.1 23.4 54.1 91.0
Antimalarials Antibiotics Analgesics
Vitamins/ immune 
boosters Face masks/ PPE
No change/ available 33 100 109 84 13
Part shortages  (1 - 2 months) 25 9 2 43
Shortages (unspecified) 53 2 2 25 55
Total 111 111 111 111 111
No change 33 100 109 84 13
% of total 29.7 90.1 98.2 75.7 11.7
Shortages % 70.3 9.9 1.8 24.3 88.3
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(26, 28). This is in line with advice and recommendations from 
the Council for International Organisations of Medical Sciences 
(170)  
• Ensure that there is active dissemination of suggested activities 
to prevent the spread of COVID-19 including sanitation in social 
media and other platforms given the increasing impact of social 
media in LMICs (171); however, mindful of the likely situation 
regarding concerns with social distancing and lack of clean water 
in many households 
• Keep track of misinformation and any false claims for medicines 
or technologies for the diagnosis and management of COVID-19 
given ongoing controversies regarding some recommended 
treatments and the financial consequences involved if scarce 
resources are diverted to purchase these products 
• Ensure swift and strict action against fraudulent advertisements 
and sale of unproven products in this time of emergency building 
on activities in other countries (172, 173) 
• Continue with planned programmes to improve the management 
of patients with chronic NCDs, reduce AMR and actively treat 
infectious diseases to minimise the unintended consequences of 
COVID-19 
• Continue to enhance local production of PPE where pertinent to 
address current shortages as well as seek mechanisms to keep 
any prices rises to a minimum (74, 81) 
• Continue to adopt a phased approach to the easing of lockdown 
measures, with rapid re-introduction if needed (174) 
Physicians • Enhance a philosophy of evidence-based medicine starting in 
medical school and continuing post qualification building on 
guideline initiatives in India (175), given current controversies 
surrounding hydroxychloroquine and lopinavir- ritonavir  
• As part of this, continue to ensure prescribed/ recommended 
treatments are evidence based through postgraduate training 
and other continuous professional development activities post 
qualification 
• Continue to encourage where possible appropriate management 
of chronic NCDs including adherence to prescribed medicines 
giving rising rates of NCDs in India 
Pharmacists • Continue to encourage, where possible, the adoption of 
recommended strategies to prevent the spread of COVID-19 
including pertinent PPE. This includes hand sanitisation as well 
as appropriate wearing of face masks 
• Try to ensure that PPE and medicines, or suitable alternatives, 
helpful for patients with COVID-19 are routinely available, and 
help ensure where possible that any price rises are kept to a 
minimum given the number of people in India going into poverty 
when family members become ill – helped by current legislation 
regarding price rises especially for essential medicines coupled 
with ongoing programmes promoting generics (20, 21) 
• Continue to argue against the need for antibiotics where this is a 
concern - helped recently by increasing recognition of the need 
for a prescription before dispensing (similar to antimalarial 
medicines)  
• Work with patients to enhance good adherence to purchased 
medicines including those for NCDs and encourage appropriate 
referrals to other professionals where pertinent especially for 
moderate to severe disease 
• Potentially become involved in vaccination programmes where 
there is unmet need as publish studies suggest that when 
pharmacists provide immunizations they substantially increase 
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• Where possible, engage with social media and channels to help 
promote evidence-based approaches to the prevention and 
management of COVID-19 given the level of misinformation 
seen to date – ensure messages are as clear as possible and in 
a positive language (174) 
• Monitor the spread of misinformation regarding the treatment of 
COVID-19 with fake or unproven medical products and 
procedures that claim to diagnose, prevent or cure COVID-19, 
and work with governments and other key stakeholder groups to 
minimise their impact (174) 
• Work with governments and other bodies regarding to minimise 
the potential consequences of COVID-19 on mental health 
issues for healthcare professionals and patients 
• Work with patients and groups to reduce concerns with stigma 
and reassure COVID-19 patients that they should pose no threat 
to the community after treatment and continue with their lives 
• Seek to educate patients/ build on current programmes 
regarding self-management in patients with chronic NCDs 
including the priority for medication adherence given lockdown 
restrictions  
• Help explore new technologies with key stakeholders including 
growing use of telemedicine approaches and other approaches 
to reduce the reliance on clinic attendance to manage NCDs 




We believe this is one of the first comprehensive studies worldwide to assess the impact of COVID-19 
on the utilisation, availability and price changes of pertinent medicines and PPE used to prevent and 
treat COVID-19 among LMICs with a high response rate (82%) among those taking part. In India high 
patient co-payments have contributed to potentially catastrophic consequences for families when 
members become ill, although this is beginning to change helped by ongoing legislation to moderate 
prices of essential medicines (1, 3, 7, 21). 
 
As expected, our study demonstrates an increase in the utilisation of a number of suggested 
medicines and PPE, enhanced by endorsement of certain approaches including increased protection 
with PPE (Table 4). However, increases in utilisation were not as great for antimalarial treatments 
(55% of pharmacies noting an increase) and antibiotics (42.3% of pharmacies noting an increase) 
compared with analgesics (67.6%) and vitamins (90.1%). This is in line initiatives by the government 
advising pharmacists not to sell antimalarials and antibiotics without a prescription. The utilisation 
patterns seen in India appear similar to the situation in Bangladesh with antimalarial tablets (48.8% of 
pharmacies and drug stores seeing an increase), analgesics (97.6% of pharmacies and drug stores 
seeing an increase) and vitamins (90.6% seeing an increase), but lower than in Bangladesh with 
respect to antibiotics (with 70.6% of stores noting an increase), perhaps reflecting greater scrutiny 
over the need for patients to have a prescription for an antibiotic in India (147).   
 
Price increases were also seen for pertinent medicines (Table 5), which was expected given some of 
the shortages seen (Table 6). However, price increases appeared appreciably lower than seen in 
Bangladesh with only 16.2% of pharmacies in India reporting a price increase for antimalarials versus 
50% in Bangladesh and only 8.1% of pharmacies in India reporting price increases for antibiotics 
versus 34.7% in Bangladesh (147). We believe this reflects greater price controls for medicines in 
India  compared with Bangladesh, providing direction to countries such as Bangladesh during the 
current pandemic and after (20, 21). A lower number of pharmacies in India (23.4%) also reported 
price increases for analgesics versus 45.3% in Bangladesh (147). This may reflect greater production 
of ingredients for medicines (API) in India than seen in Bangladesh coupled with Government price 
controls (21). However, further research will be needed before any definitive statement can be made 
especially as shortages of antimalarials were seen in India during the study period (70.3% of 
pharmacies), although this was only short term in a third of these (Table 6). Shortages of antimalarial 
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medicines were seen in 54.1% of pharmacies and drug stores in Bangladesh during the same period 
(147).  
 
As mentioned, we observed an appreciable increase in the use of PPE in both Bangladesh (over 95% 
of pharmacies and drug stores respectively) and India (98.2% respectively) during the study period 
(147). This was typically accompanied by shortages and price rises in both countries, some of which 
were substantial (147). We have also seen substantial increase in the price of PPE in other LMICs as 
the pandemic progresses (177).  
 
Table 7 highlights potential activities that can be undertaken by key stakeholder groups in India and 
more widely to address issues and concerns with COVID-19. This includes addressing unintended 
consequences of COVID-19 including issues of stigma as well as addressing concerns with 
appropriate identification and management of other infectious diseases apart from COVID-19 as well 
as among patients with chronic NCDs given rising rates of coronary vascular disease in India. We will 
be monitoring the situation with respect to hydroxychloroquine given ongoing controversies across 
countries.  
 
We are aware of a number of limitations with this study. These include the fact that we were unable to 
obtain exact details on changes in the utilisation and prices of pertinent medicines and PPEs from all 
the pharmacists visited due to issues of confidentiality and having the data readily to hand. We also 
did not cover all the regions in India. In addition, we did not break down antibiotics into azithromycin 
and other antibiotics such as amoxycillin in view of the study constraints. We also did not ask about 
shortages of other medicines such as those to treat patients with NCDs. Alongside this, we are aware 
that some of the shortages initially may have been due to transport and logistic issues. A number of 
these issues will be addressed in future studies. However, we are confident our findings can be 
helpful for future planning purposes in India and wider given the number of community pharmacies 




In our study we have seen increases in utilisation and prices as well as shortages of pertinent 
medicines and PPE used to prevent and treat COVID-19 in India. Encouragingly, the extent of 
shortages and price increases in India were not as high as originally expected, potentially helped by 
local production of medicines, including the active ingredients, greater scrutiny over the dispensing of 
antimalarials and antibiotics without a prescription, as well as government control over prices 
including recently; with similarities with Bangladesh. There are ongoing concerns and challenges 
regarding potential treatments including antimalarials, which needs urgent addressing. Increasing 
recognition of the need for evidence-based medicine in terms of treatment recommendations and 
prescribing can help further reduce inappropriate treatments being recommended, prescribed or 
dispensed. Patient organisations can also play a role through social media and other platforms to 
reduce the extent of misinformation and its potential damaging consequences. We will be monitoring 
this in the future.     
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Appendix 1 – Questionnaire to community pharmacists in India  
 
The Questionnaire is designed to ascertain changes in the utilisation, prices and shortages of 
possible medicines and equipment to prevent and treat patients with COVID-19. You are free to 
participate or not, and confidentiality will be maintained. 
 
Question 1: What is your location (City and region)? 
 
Question 2: What changes in medicine purchasing patterns have you noticed in your pharmacy from 
the beginning of March, i.e. soon after the start of the pandemic but before major travel and other 
restrictions until the end of May, for antimalarials (hydroxychloroquine), antibiotics (e.g. azithromycin 
and co-amoxiclav), multivitamins including Vitamin C and analgesics? [Please note - This is based on 
invoices where possible from prior to the beginning of March or other information sources; 
alternatively impressions (free text)] 
 
Question 3: What changes in prices have you noticed in your pharmacy from the beginning of March 
until the end of May, for antimalarials (hydroxychloroquine), antibiotics (e.g. azithromycin and co-
amoxiclav), multivitamins including Vitamin C and analgesics? [Please note - This is based on 
invoices where possible from prior to the beginning of March or other information sources; 
alternatively impressions (free text)] 
 
Question 4: Have there been any shortages for antimalarials (hydroxychloroquine), antibiotics (e.g. 
azithromycin and co-amoxiclav), multivitamins including Vitamin C or analgesics in your pharmacy 
from the beginning of March until the end of May, for antimalarials (hydroxychloroquine), antibiotics 
(e.g. azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics? If so, what is 
the extent of any shortages (free text)? 
 
Question 5: What has been the changes in utilisation, prices and potential shortages for personal 
protection equipment (PPE) such as hand sanitisers and face masks in your pharmacy from the 
beginning of March until the end of May? [[Please note - This is based on invoices where possible 
from prior to the beginning of March or other information sources; alternatively impressions (free text)] 
 
Question 6: What suggestions do you have for the authorities in India to reduce misinformation 
regarding different management and treatment approaches for new pandemics as well as reduce 
inappropriate self-medication with antimicrobials (free text)? 
 
